Affordable Insulin for the COVID-19 Emergency Act This bill eliminates cost-sharing under the Medicare prescription drug benefit and Medicare Advantage for insulin and associated medical supplies during the public health emergency relating to COVID-19 (i.e., coronavirus disease 2019). The bill also allows beneficiaries to receive their insulin and supplies via mail order during the emergency period.
This resolution recognizes the disparity between wages paid to men and women, and its impact on women, families, and the nation and reaffirms Congress' commitment to supporting equal pay and to narrowing the gender wage gap.
Water Affordability, Transparency, Equity, and Reliability Act of 2021 This bill provides funding for several programs related to controlling water pollution or protecting drinking water, revises requirements concerning the clean water state revolving fund (SRF) and the drinking water SRF, and creates or reauthorizes several grant programs for water infrastructure. For example, the Environmental Protection Agency must establish a grant program for repairing, replacing, or upgrading septic tanks and drainage fields. In addition, the bill makes permanent a grant program for household water well systems in rural areas. It also increases the amount of appropriations for grant programs, including a program that awards grants to prevent lead from contaminating drinking water fountains in schools and day care facilities.
Intercity Passenger Rail Trust Fund Act This bill establishes in the Treasury an Intercity Passenger Rail Trust Fund designed to ensure a safe, sustainable, convenient transportation option for the people of the United States. Amounts in the fund may be used by the Department of Transportation to award grants to the National Railroad Passenger Corporation (Amtrak) for activities associated with the Northeast Corridor and the National Network (Amtrak's state-supported and long-distance service lines).
Data Care Act of 20 21 This bill imposes various duties on online service providers with respect to their handling of individual-identifying data that can be reasonably linked to a specific user. Specifically, online service providers have a duty to (1) reasonably secure such data from unauthorized access, (2) refrain from using such data in a way that will result in reasonably foreseeable harm to the end user, and (3) not disclose such data to another party unless that party is also bound by the duties established in this bill. The bill authorizes the Federal Trade Commission and specified state officials to take enforcement actions with respect to breaches of such duties.
Prescription Drug Price Relief Act of 2021 This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.
Funding Attorneys for Indigent Removal Proceedings Act or the FAIR Proceedings Act This bill expands access to counsel for aliens in immigration proceedings and provides for protections related to such proceedings. An alien shall have the privilege of being represented by counsel in any immigration proceeding, whereas currently this privilege is statutorily provided for only in removal proceedings. Similarly, the Department of Justice (DOJ) may provide counsel at government expense to aliens in any immigration proceeding, whereas currently DOJ is statutorily authorized to provide counsel to aliens only in removal proceedings and at no expense to the government. Under this bill, DOJ shall provide counsel to children and vulnerable individuals in such proceedings, at government expense if necessary. If DOJ fails to do so, certain limits on filing a motion to reopen removal proceedings (such as the time limit for filing) shall not apply, and the alien's removal shall be stayed upon the motion's filing. The Department of Homeland Security (DHS) shall provide each alien, generally at the beginning of proceedings, a complete copy of the alien's case file in DHS possession, unless the alien waives this right in writing. Failure to provide such documents shall delay the alien's removal proceeding. DHS shall facilitate for all detained aliens access to counsel and programs that inform such aliens of their immigration-related rights and obligations.
Transparency in Classification Act of 2021 This bill establishes the Interagency Security Classification Appeals Panel, a body to review decisions related to the classification of information, and contains other related provisions. The appeals panel shall provide the public and authorized users of the classification system with a forum to request review of agency classification decisions. It shall also provide members of Congress a mechanism for expedited reviews of classification decisions. Each agency that handles classified information shall establish a policy for an individual authorized to access classified information to request a review of a classification decision. Such an individual may also appeal a classification decision to the appeals panel. Appeals panel decisions may be appealed to the President. The bill imposes various requirements related to the appeals processes created under this bill, including time lines for rendering decisions. The appeals panel shall establish a public website with information about all appeals requests that it has received.
COVID-19 Disinformation Research and Reporting Act of 2021 This bill requires the National Science Foundation to contract with the National Academies of Sciences, Engineering, and Medicine to study disinformation and misinformation about COVID-19 (i.e., coronavirus disease 2019) on the internet and social media platforms.
Survivors' Access to Supportive Care Act or SASCA This bill sets out programs and requirements to address access and quality issues related to sexual-assault examinations. Specifically, the bill establishes training and technical assistance programs for health care providers on conducting sexual-assault examinations and treating survivors of sexual assault, including in rural and tribal settings; grants for states to assess the availability of trained providers to perform sexual-assault examinations; and a task force to assist state-level efforts to improve medical forensic evidence collection related to sexual assault. The bill also requires institutions of higher education to provide information about the availability of sexual-assault examinations to survivors of sexual assault. Additionally, hospitals and specified components of the Department of Health and Human Services (HHS) must report on access and quality issues concerning sexual-assault examinations and related services. Furthermore, HHS must address access to, and the quality of, trained health care providers who conduct sexual-assault examinations in the National Quality Strategy. This is a national effort to align public-sector and private-sector stakeholders to achieve better health and health care.
Integrity, Notification, and Fairness in Online Retail Marketplaces for Consumers Act or the INFORM Consumers Act This bill requires online marketplaces to collect, verify, and disclose certain information from high-volume, third-party sellers. High-volume, third-party sellers include online marketplace participants that conduct 200 or more transactions resulting in total revenues of $5,000 or more during a continuous 12-month period. Online marketplaces must acquire these sellers' (1) bank account numbers, (2) government-issued identification, (3) tax identification numbers, and (4) contact information. Online marketplaces must verify this information and annually certify any changes to it. Further, online marketplaces must make certain information (e.g., sellers' names and contact information) available to consumers through the sellers' product listings and provide consumers with methods to report electronically and by telephone any suspicious activity on the marketplace. The bill provides the Federal Trade Commission with the authority to enforce these requirements.
Medicare Drug Price Negotiation Act This bill makes a series of changes relating to the prices of prescription drugs under the Medicare prescription drug benefit and Medicare Advantage (MA) prescription drug plans (PDPs). Under current law, the Centers for Medicare & Medicaid Services (CMS) may neither negotiate the prices of covered drugs nor establish a formulary. The bill repeals these restrictions and instead specifically requires the CMS to (1) negotiate the prices of covered drugs; and (2) either establish a formulary for covered drugs, or require changes to PDP formularies that take into account CMS negotiations. If the CMS is unable to negotiate an appropriate price for a drug in accordance with certain criteria, the price must be the lowest of three specified options (e.g., the median price in other countries). The CMS must identify drugs that are subject to negotiation, with priority given to certain categories of drugs based on usage and cost. Additionally, drug manufacturers must issue rebates to the CMS for drugs dispensed to eligible low-income individuals. Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.
